Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy

Charles J. Rosser, Ashish M. Kamat, Xuemei Wang, Kim Anh Do, Yoshio Naya, David C. Hoover, Patricia Troncoso, Ricardo F. Sanches-Ortiz, Louis L. Pisters

Research output: Contribution to journalArticle

9 Scopus citations


Objectives: To determine the biochemical disease-free survival rates in patients 60 years old or younger who were treated with surgery for localized prostate cancer. Methods: We reviewed the medical records of 291 patients 60 years old or younger who had undergone radical prostatectomy as the sole primary treatment for prostate cancer. Follow-up prostate-specific antigen (PSA) levels were measured 6 to 8 weeks after surgery and 4 to 6 months thereafter. Biochemical failure was defined as a detectable PSA level (greater than 0.01 ng/mL). The median follow-up of the entire study group was 50 months. Results: Eighty-one percent of the patients presented with a serum PSA level of 10 ng/mL or less, and 52% had a Gleason score of less than 7 on prostate biopsy. The radical prostatectomy specimens showed organ-confined disease in 72% of patients, and 83% of tumors had a Gleason score of 7. The 1, 5, and 7-year biochemical disease-free survival rate was 99%, 91%, and 91%, respectively. The fitted multivariate Cox proportional hazards model showed that having a prostatectomy specimen Gleason score greater than 7 or seminal vesicle invasion or nodal disease significantly increased the risk of biochemical failure. Conclusions: In the PSA era, men with prostate cancer who are 60 years old or younger and treated with surgery have an excellent biochemical disease-free outcome.

Original languageEnglish (US)
Pages (from-to)769-773
Number of pages5
Issue number4
StatePublished - Apr 1 2006


ASJC Scopus subject areas

  • Urology

Cite this